#POAI

@prismmarketview.bsky.social

3 months ago

December’s Hidden Risk: Investing in the Age of Identity Theft During National Identity Theft Prevention and Awareness Month, consumers may guard their passwords, but the financial world is focused on the new identity asset

December’s Hidden Risk: Investing in the Age of Identity Theft
#TSL #CISCO #POAI #ATH
prismmarketview.com/decembers-hi...

0 0 0 0

StockTitan

@stocktitan.net

4 months ago

Predictive Oncology Reports Third Quarter 2025 Financial Results and Provides Update on Digital Asset Strategy Predictive Oncology (Nasdaq: POAI) reported Q3 2025 results and launched a digital asset treasury strategy centered on ATH, Aethir’s native token. The company completed two private placements raising approximately $50.8 million in cash and receiving in-kind ATH with a notional value of about $292.7 million at signing. As of Nov 10, 2025, POAI held ~5.70 billion ATH with a market value of ~$152.8 million (price $0.0268 per ATH), of which 3.7 billion are locked.Q3 operating revenue was $3,618, cash was $181,667, stockholders’ deficit was $77.4 million, and POAI recorded a $74.4 million derivative liability tied to the ATH strategy; basic/diluted loss per share was $(107.24).

#POAI Predictive Oncology Reports Third Quarter 2025 Financial Results and Provides Update on Digital Asset Strategy

www.stocktitan.net/news/POAI/predictive-onc...

0 0 0 0

Market Wire News

@marketwirenews.com

5 months ago

BREAKING NEWS: ( NASDAQ: #POAI ) CryptoNewsBreaks - Predictive Oncology Inc. (NASDAQ: POAI) Prices $344.4 Million in PIPEs to Launch Digital Asset Treasury Strategy

0 0 0 0

StockTitan

@stocktitan.net

5 months ago

Predictive Oncology Inc. Announces Private Placements of $344 Million to Initiate a Digital Asset Treasury Strategy Focused on Aethir (ATH) Tokens Shawn Matthews, CEO of DNA Holdings and Former CEO of Cantor Fitzgerald, will join the Board of Directors upon the closing of the private placements Predictive Oncology continues to execute on its artificial intelligence and machine learning business to expedite early drug discovery and enable drug

#POAI Predictive Oncology Inc. Announces Private Placements of $344 Million to Initiate a Digital Asset Treasury Strategy Focused on Aethir (ATH) Tokens

www.stocktitan.net/news/POAI/predictive-onc...

0 0 0 0

StockTitan

@stocktitan.net

6 months ago

150,000 Tumor Sample Analysis: Predictive Oncology and Every Cure Unite to Fast-Track Cancer Drug Discovery AI biotech partnership leverages 150,000 tumor samples across 130 cancer types to repurpose FDA-approved drugs. Platform aims to deliver treatments in months vs decades at reduced costs.

#POAI Predictive Oncology and Every Cure Announce a Strategic Collaboration to Pursue Drug Repurposing for Cancer Patients

www.stocktitan.net/news/POAI/predictive-onc...

0 0 0 0

StockTitan

@stocktitan.net

7 months ago

Predictive Oncology's ChemoFx Test Could End Trial-and-Error Cancer Treatment as Company Eyes Global Expansion AI-driven biotech firm advances ChemoFx cancer treatment selection test for Q4 launch, leveraging 150,000 tumor sample database. Secures $10M equity agreement. See details.

#POAI Predictive Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/POAI/predictive-onc...

0 0 0 0

StockTitan

@stocktitan.net

8 months ago

AI Drug Discovery Breakthrough: Predictive Oncology Lands $10M Deal to Accelerate Cancer Research Innovation Strategic $10M equity agreement with Yorkville Advisors empowers Predictive Oncology's AI-driven drug discovery platform. See how this flexible funding advances cancer research.

#POAI Predictive Oncology Announces $10M Share Purchase Agreement in Partnership with Yorkville Advisors to Advance AI-Driven Drug Discovery and Repurposing

www.stocktitan.net/news/POAI/predictive-onc...

0 0 0 0

StockTitan

@stocktitan.net

9 months ago

Predictive Oncology Develops Functional 3D Organoid Models Exclusively for Labcorp Predictive Oncology (NASDAQ: POAI) has developed exclusive 3D liver toxicity organoid models for Labcorp (NYSE: LH), including human and rat variants, to enhance drug discovery and toxicity testing. These models simulate liver microenvironments to predict drug clearance, transport, and hepatotoxicity. The technology leverages POAI's extensive biobank of 150,000+ frozen tumor samples and complements their AI-driven 2D platform and 3D spheroids. The models demonstrated optimal liver morphology and function through various tests, including cell junction formation and hepatotoxicity measurements. This development aligns with the growing organoid-based platform market, which aims to accelerate drug development while reducing reliance on animal testing.

#POAI Predictive Oncology Develops Functional 3D Organoid Models Exclusively for Labcorp

www.stocktitan.net/news/POAI/predictive-onc...

0 0 0 0

StockTitan

@stocktitan.net

9 months ago

Delaware Court Rejects Renovaro's Rush to Trial Against Predictive Oncology, Cites Critical Delays Delaware Court pushes trial to November, citing Renovaro's delayed filing. See why the Court denied expedited proceedings and what's next for both companies.

#POAI Court Denies Renovaro Motion for an Expedited Trial in July

www.stocktitan.net/news/POAI/court-denies-r...

0 0 0 0

StockTitan

@stocktitan.net

9 months ago

Major AI Breakthrough: How 150,000 Live Tumor Samples Are Revolutionizing Cancer Drug Discovery Groundbreaking AI platform successfully predicts drug responses across 137 cancer types using world's largest live tumor biobank. See breakthrough results.

#POAI AI Meets Genomics: Predictive Oncology Breakthrough Coincides with Regeneron's $256M 23andMe Acquisition

www.stocktitan.net/news/POAI/ai-meets-genom...

0 0 0 0

StockTitan

@stocktitan.net

9 months ago

Predictive Oncology Inc. Issues Shareholder Letter Titled, "Revolutionizing Medicine: AI-Driven Biomarker and Drug Discovery for Precision Health" Predictive Oncology (NASDAQ: POAI) has shared significant progress in its AI-driven drug discovery and biomarker development initiatives. The company has achieved key milestones including: successful development of AI-powered survival prediction models for ovarian cancer in collaboration with UPMC Magee-Womens Hospital, identification of novel cancer biomarkers, and expansion of their ChemoFx® assay into Europe. The company leverages its biobank of 150,000 tumor samples across 137 cancer types to validate AI drug response predictions. Operating in the biomarker discovery market, valued at $14.5 billion in 2024 with projected 19.4% CAGR through 2030, POAI is exploring strategic partnerships and advancing drug repurposing initiatives, having identified three promising candidates for ovarian and colon cancer treatment.

#POAI Predictive Oncology Inc. Issues Shareholder Letter Titled, "Revolutionizing Medicine: AI-Driven Biomarker and Drug Discovery for Precision Health"

www.stocktitan.net/news/POAI/predictive-onc...

0 0 0 0

StockTitan

@stocktitan.net

10 months ago

Predictive Oncology Earnings: AI Platform Identifies 3 Promising Cancer Drug Candidates as Revenue Jumps 2170% AI-powered drug discovery breakthrough reveals 3 promising cancer candidates. Revenue surges 2170% YoY, cash position strengthens to $3.1M. See full financial details.

#POAI Predictive Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/POAI/predictive-onc...

0 0 0 0

StockTitan

@stocktitan.net

11 months ago

Revolutionary AI Platform Revives Abandoned Cancer Drugs with Stunning Results Novel AI-powered screening identifies three forgotten cancer drugs outperforming standard treatments in breast and colon cancers. Full analysis inside.

#POAI Predictive Oncology Develops Novel Approach to Identifying Clinically Viable Abandoned Drugs

www.stocktitan.net/news/POAI/predictive-onc...

0 0 0 0

StockTitan

@stocktitan.net

11 months ago

Predictive Oncology Advances AI Merger Plans Despite $10.8M Loss: Key Strategic Moves Revealed Latest earnings reveal Predictive Oncology's strategic pivot: Renovaro merger progress, AI platform integration, and European expansion plans. Full analysis of key metrics inside.

#POAI Predictive Oncology Reports Year-End 2024 Financial Results and Provides Corporate Update

www.stocktitan.net/news/POAI/predictive-onc...

0 0 0 0

Market Wire News

@marketwirenews.com

11 months ago

NEWS: ( NASDAQ: #POAI ) Predictive Oncology Breaks New Ground with AI-Driven Models for Cancer-Fighting Compounds

1 0 0 0

StockTitan

@stocktitan.net

11 months ago

Revolutionary AI Platform Discovers Superior Cancer Treatments in Record Time Advanced AI identifies novel compounds showing stronger tumor response than standard drug across breast, colon, and ovarian cancers, cutting research time by 93%. Full analysis inside.

#POAI Predictive Oncology Successfully Develops Predictive Models Derived from Never-Before-Seen Compounds for Prevalent Cancer Indications Including Breast, Colon and Ovary

www.stocktitan.net/news/POAI/predictive-onc...

0 0 0 0

StockTitan

@stocktitan.net

11 months ago

Strategic Pivot: Predictive Oncology Divests Medical Assets for AI-Powered Future Predictive Oncology completes strategic sale of Skyline Medical to DeRoyal Industries, sharpening focus on AI-driven drug discovery ahead of Renovaro Biosciences merger.

#POAI Predictive Oncology Completes Sale of Skyline Medical Assets to DeRoyal Industries

www.stocktitan.net/news/POAI/predictive-onc...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Can This AI-Powered Oncology Merger Transform Cancer Treatment? First Financing Milestone Reached Predictive Oncology advances merger with Renovaro Biosciences, combining AI drug discovery platforms and 150,000+ tumor sample biobank to revolutionize cancer treatment.

#POAI Predictive Oncology Moves to Finalize Definitive Merger Agreement With Renovaro Biosciences

www.stocktitan.net/news/POAI/predictive-onc...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Predictive Oncology Closes Registered Direct Offering Predictive Oncology (NASDAQ: POAI) has successfully closed its previously announced registered direct offering, selling 363,336 shares of common stock at $1.50 per share, priced at-the-market under Nasdaq rules. The offering generated gross proceeds of approximately $545,004 before deducting placement agent fees and other expenses. H.C. Wainwright & Co. served as the exclusive placement agent.The company plans to utilize the net proceeds for working capital and general corporate purposes. The offering was conducted under a shelf registration statement on Form S-3 that became effective on May 21, 2024. A final prospectus supplement and accompanying prospectus were filed with the SEC on February 19, 2025.

#POAI Predictive Oncology Closes Registered Direct Offering

www.stocktitan.net/news/POAI/predictive-onc...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Inside Predictive Oncology's Latest Capital Raise: Key Details of the $545K Direct Offering AI-driven biotech secures $545K through at-market offering of 363,336 shares at $1.50, with proceeds targeted for working capital and corporate needs.

#POAI Predictive Oncology Announces Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

www.stocktitan.net/news/POAI/predictive-onc...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

AI Drug Discovery Milestone: Predictive Oncology Finds Cancer Treatment Gold in Abandoned Drugs AI platform identifies promising cancer drug candidates with 10x efficiency, discovering treatments outperforming standard therapy for colon cancer

#POAI Predictive Oncology Reports Positive Results Utilizing Artificial Intelligence for Drug Repurposing

www.stocktitan.net/news/POAI/predictive-onc...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Predictive Oncology Expands Revolutionary Cancer Drug Testing Platform to Europe ChemoFx® assay, previously generating $25M annually, returns to market targeting 365,000 gynecological cancer cases across US and Europe with personalized treatment testing.

#POAI Predictive Oncology Announces Planned European Launch of its ChemoFx® Treatment Selection Marker and Tumor Profiling Assay

www.stocktitan.net/news/POAI/predictive-onc...

0 0 0 0